Price and states served both move. Read them off the seller's own site before you enroll.How our reviews work →

1st Optimal vs Invyncible

An in-depth comparison of two leading GLP-1 Providers

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

By Ruth Calder · Enforcement Editor
Editorially reviewed & fact-checked against primary sources · How we verify contentLast reviewed
1st Optimal logo

1st Optimal

3.9
★★☆☆☆2/5

Best for: coaching bundled into the price rather than sold separately

Visit 1st Optimal
VS
Invyncible logo

Invyncible

6.7
★★★☆☆3.4/5

Best for: compounded tirzepatide at $210/month

Visit Invyncible

Two GLP-1 Providers chasing the same patients, trading off price, geography and what lands in the box differently. On our scoring, Invyncible starts at $192.5/mo, and Invyncible finishes ahead, 6.7 to 3.9. What follows: the prices, what each plan actually covers, the six-dimension score, where each one is weak, and who should pick which.

Pricing

1st Optimal

Pricing not publicly listed.

Invyncible

Semaglutide Injections Program — starter vial (~0.5 mg weekly, 2.5 mg vial, roughly 5 weeks)Compounded
$192.5/mo
semaglutide

Listed at $192.50 against a $275.00 list price. Programs are sold per vial with an approximate duration, not as a calendar month — see the review notes.

Tirzepatide Injection Program — standard formulaCompounded
$210/mo
tirzepatide

Listed at $210.00 against a $300.00 list price. Cheaper combination formulas exist: tirzepatide/glycine/B12 $180.00 and semaglutide/glycine/B12 $149.00.

What’s included

1st Optimal

Covered by the monthly price

Medication

Not stated

Clinician visits

In the price

Shipping

In the price

Lab work

Not stated

Coaching

In the price

Invyncible

Inclusions not disclosed.

Score breakdown

Both providers are scored on the same six-dimension framework. The gradient bar marks the stronger side on each dimension.

1st Optimal

3.9/10

Overall

Invyncible

6.7/10

Value25%

3.0A
vs
B
6.7

Effectiveness25%

5.0A
vs
B
10.0

User Experience15%

2.0A
vs
B
3.0

Trust & Safety15%

4.0A
vs
B
5.0

Accessibility10%

5.0A
vs
B
8.4

Support10%

5.0A
vs
B
5.0

Features & Coverage

Feature1st OptimalInvyncible
Starting Price$192.5/mo
Features8 features6 features
States AvailableNot disclosed40
Compounded✓ Yes
Brand Name
FSA/HSA Accepted
FDA WarningsNoneNone

About 1st Optimal

Neither a monthly price nor a list of states is published. 1st Optimal operates out of Michigan across telehealth and functional medicine, writing the GLP-1s semaglutide and tirzepatide either as a weekly injection or as a daily oral tablet. Around the prescription it stacks at-home lab testing, interpretation of the blood work, coaching without limit and protocols built individually, all framed as long-term weight loss and longevity. Credentialed providers work virtually, treatment goes to the home, and nothing binds you to a long contract.

Read our full 1st Optimal review →

About Invyncible

Invyncible does not publish its pricing tiers; they surface only after the sign-up flow. The Florida-based platform sells semaglutide and tirzepatide programs for weight management, openly discloses its corporate parent and physical address where competitors hide ownership behind a trade name, and displays a LegitScript verification seal. There is no long-term commitment.

Read our full Invyncible review →

Pros & Cons

1st Optimal

What we like

  • The monthly figure covers consult, shipping, coaching
  • No FDA warning letter matched this operator when we searched our enforcement register
  • A live video visit with a clinician is required before a prescription, which is slower than a form and is the more careful intake
  • Baseline bloodwork is required before a prescription

Watch-outs

  • No price appears until the medical intake is complete, so the cost cannot be compared before health information is submitted
  • No state list is on record here, so whether it serves your state cannot be confirmed from this page
  • No dispensing pharmacy is named in our record, so its accreditation cannot be looked up from here

Invyncible

What we like

  • Tirzepatide at $210 a month, within the normal band around this register's $267 median for the same drug and form
  • Coverage is published for 40 states
  • No FDA warning letter matched this operator when we searched our enforcement register

Watch-outs

  • No price appears until the medical intake is complete, so the cost cannot be compared before health information is submitted
  • No dispensing pharmacy is named in our record, so its accreditation cannot be looked up from here
  • Its semaglutide and tirzepatide are compounded rather than FDA-approved, so they have not been reviewed by the agency for safety, effectiveness or manufacturing quality

Our Verdict

Winner: Invyncible

Invyncible takes it, 6.7 against 3.9, and it is especially strong on compounded tirzepatide at $210/month. 1st Optimal is no weak second and may fit you better on coaching bundled into the price rather than sold separately.

Choose 1st Optimal if…

You want coaching bundled into the price rather than sold separately.

Choose Invyncible if…

You want compounded tirzepatide at $210/month and an opening price near $192.5 a month.

Ready to start? Vetted GLP-1 providers

Vetted telehealth providers that prescribe GLP-1 online.

No insurance needed · vetted by our editors

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

8.8

Found

Tirzepatide at $169/month, 37% under the register median

8.3

Telos Rx

Starting below a standard dose, with microdose tiers

7.0

MyDrHank

An oral route if you will not self-inject

1st Optimal vs Invyncible: FAQ

Glossary

The words sellers use, defined. Tap any term.

Continue exploring 1st Optimal and Invyncible head-to-heads in the same category.

Or see the full category ranking.

Novo Nordisk A/S owns the Wegovy®, Ozempic® and Rybelsus® marks; Eli Lilly and Company owns Mounjaro® and Zepbound®. Every other product name and mark on this page belongs to whoever owns it. No pharmaceutical manufacturer is affiliated with GLP Watchdog. See trademark disclaimer.